β-磷酸三钙在良性肿瘤术后骨缺损中的应用的临床结果。
Clinical Outcome of Beta-Tricalcium Phosphate Use for Bone Defects after Operative Treatment of Benign Tumors.
机构信息
Department of Orthopedic Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.
出版信息
Clin Orthop Surg. 2019 Jun;11(2):233-236. doi: 10.4055/cios.2019.11.2.233. Epub 2019 May 9.
BACKGROUND
We investigated the clinical outcome in patients whose cavitary bone defects were treated with beta-tricalcium phosphate (β-TCP) after surgical removal of benign tumors.
METHODS
Between March 2015 and December 2015, 20 patients who underwent operation for bone tumors were enrolled into this study and prospectively followed up for a median period of 28.1 months.
RESULTS
When the radiographic sign of complete resorption was defined as greater than 50% resorption of the allograft material accompanied by bone remodeling until 12 months, 55% of patients had complete resorption. Positive correlation between the filling volume and time needed for complete resorption was not found ( = 0.184).
CONCLUSIONS
Purified β-TCP could be a suitable choice as a bone graft substitute after the removal of benign bone tumors.
背景
我们研究了在良性肿瘤切除术后使用β-磷酸三钙（β-TCP）治疗腔隙性骨缺损患者的临床结果。
方法
2015 年 3 月至 2015 年 12 月期间，我们对 20 例因骨肿瘤接受手术的患者进行了前瞻性研究，并进行了中位数为 28.1 个月的随访。
结果
当将完全吸收的影像学标志定义为大于 50%的同种异体材料吸收，伴有骨重建，直至 12 个月时，55%的患者有完全吸收。填充体积与完全吸收所需时间之间无正相关关系（=0.184）。
结论
在良性骨肿瘤切除术后，纯化的β-TCP 可作为一种合适的骨移植替代物。
Zotero 插件